TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32576633

Group type: EXPERIMENTAL
Intervention: Clinical score (0 to 12 points) based on 6 variables: seizure(s) at presentation, known thrombophilia, oral contraception, duration of symptoms >6 days, worst headache ever, focal neurologic deficit at presentation.
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: D-dimers >675 μg/L (best cutoff)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: D-dimers >500 μg/L
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Combination of clinical score and D-dimers >500 μg/L
Number of subjects: 359
Study: 32577626

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E immunogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA immunogen
Number of subjects: 0
Study: 32577878

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) with intraoperative monitoring (IOM)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Comprehensive spasticity program
Number of subjects: 146
Study: 32578220

Group type: EXPERIMENTAL
Intervention: IVF therapy
Number of subjects: 275
Study: 32578441

Group type: EXPERIMENTAL
Intervention: RIPK1 kinase inhibitor (Nec-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Littermate control mice
Number of subjects: 0
Study: 32578481

Group type: EXPERIMENTAL
Intervention: Baseline to 1-year follow-up
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: SAQ-7 improvement
Number of subjects: 214
Study: 32578962

Group type: EXPERIMENTAL
Intervention: Community-acquired AKI (CA-AKI)
Number of subjects: 1643

Group type: COMPARATOR
Intervention: In-hospital AKI
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Haemoconcentration
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Transglomerular pressure gradient
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Urinary NGAL ratio concentrations
Number of subjects: 1643
Study: 32578964

Group type: EXPERIMENTAL
Intervention: Sequential bortezomib (BTZ) 1.3 mg/m² intravenously + temozolomide (TMZ) therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 32579086

Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 22
Study: 32579284

Group type: EXPERIMENTAL
Intervention: Severely depressed subtype
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mixed depression-mania subtype
Number of subjects: 150

Group type: COMPARATOR
Intervention: Minimal symptom subtype
Number of subjects: 150

Group type: COMPARATOR
Intervention: Mania subtype
Number of subjects: 150

Group type: COMPARATOR
Intervention: Moderately depressed subtype
Number of subjects: 150
Study: 32579796

Group type: EXPERIMENTAL
Intervention: Intravenous rivipansel (840 mg) in subjects with renal impairment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous rivipansel (840 mg) in subjects with normal renal function
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous rivipansel (840 mg) in subjects with moderate hepatic impairment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous rivipansel (840 mg) in subjects with normal hepatic function
Number of subjects: 44
Study: 32580249

Group type: EXPERIMENTAL
Intervention: Subsequent surgical and nonsurgical therapies after primary treatment failure
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Vinblastine monotherapy
Number of subjects: 1558

Group type: COMPARATOR
Intervention: First-line adjuvant treatment
Number of subjects: 1558
Study: 32580252

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 6938

Group type: EXPERIMENTAL
Intervention: Drape
Number of subjects: 6938

Group type: COMPARATOR
Intervention: Alcohol scrub and iodophor drape
Number of subjects: 6938

Group type: EXPERIMENTAL
Intervention: One-minute alcohol scrub and drape
Number of subjects: 6938
Study: 32580586

Group type: EXPERIMENTAL
Intervention: Coronary Access (CA) after TAVI
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) after TAVI
Number of subjects: 1936
Study: 32580597

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cells
Number of subjects: 0
Study: 32580743

Group type: EXPERIMENTAL
Intervention: Optimized lunch menu (GHGE-reduced, nutritionally adequate, and affordable) served for four weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline lunch menu served for four weeks.
Number of subjects: 0
Study: 32580757

Group type: EXPERIMENTAL
Intervention: Hyperuricemia (SUA > 7 mg/dL in males and > 6 mg/dL in females)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Normouricemia (SUA ≤ 7 mg/dL in males and ≤ 6 mg/dL in females)
Number of subjects: 560
Study: 32580982

Group type: EXPERIMENTAL
Intervention: Zero Childhood Cancer Personalised Medicine Program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formative Evaluation Feedback Loops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social network analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert panel recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Summative evaluation of the Program
Number of subjects: 0
Study: 32580988

Group type: EXPERIMENTAL
Intervention: Septic cardiomyopathy assessment and comprehensive cardiovascular and molecular deep phenotyping including echocardiographic and electrocardiographic assessment, heart rate variability, body composition, mitochondrial oxygen metabolism, macrocirculation and microcirculation, endothelial barrier function, routine immunological, haematological and biochemical tests, serum metabolome and lipidome analyses, microbiome and epigenetic modifications of immune cells.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of patients with cardiomyopathy without infection and healthy subjects.
Number of subjects: 0
Study: 32580987

Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure in the first year of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disruption of the infant oral and intestinal microbiome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compositional overlap between maternal intestinal microbiome, breast milk microbiome, and infant oral and intestinal microbiome
Number of subjects: 0
Study: 32581505

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Prior-ranibizumab eyes
Number of subjects: 229
Study: 32581513

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa enzyme replacement therapy (ERT)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa ERT
Number of subjects: 560
Study: 32581744

Group type: EXPERIMENTAL
Intervention: Bilateral GPi and bilateral PPN region deep brain stimulation (DBS) electrodes
Number of subjects: 5
Study: 32581767

Group type: EXPERIMENTAL
Intervention: EAHE (Erinacine A-Enriched) mycelia capsules, 5 mg/g, three capsules per day for 49 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules, identical in appearance to EAHE capsules, for 49 weeks
Number of subjects: 0
Study: 32581961

Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training (RRT) administered for 13 hours over 9 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual Hemisphere-Specific Stimulation (VHSS) + Action Video Game Training (AVG) administered for 13 hours over 9 days
Number of subjects: 0
Study: 32582156

Group type: EXPERIMENTAL
Intervention: Allogenic Adipose Tissue-Derived Stromal/Stem Cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32582547

Group type: EXPERIMENTAL
Intervention: P10s-PADRE vaccine
Number of subjects: 8
Study: 32582585

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 0
Study: 32582595

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32582613

Group type: EXPERIMENTAL
Intervention: Clean Fuel Cooking Programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32582758

Group type: EXPERIMENTAL
Intervention: S-TRAC trial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32582855

Group type: EXPERIMENTAL
Intervention: Three-dimensional orientation reconstruction of nanoscale features and biomineral crystal lattice using small-angle x-ray scattering and wide-angle x-ray scattering.
Number of subjects: 0
Study: 32583052

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 108
Study: 32583288

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score (considered as continuous variable)
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: ATRIA score (considered as continuous variable)
Number of subjects: 1766

Group type: COMPARATOR
Intervention: CHA2DS2-VASc score (considered as categorical variable)
Number of subjects: 1766

Group type: COMPARATOR
Intervention: ATRIA score (considered as categorical variable)
Number of subjects: 1766
Study: 32583306

Group type: EXPERIMENTAL
Intervention: Active cancer patients
Number of subjects: 10684

Group type: COMPARATOR
Intervention: Cancer patients (active and history)
Number of subjects: 10684
Study: 32583749

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon Angioplasty
Number of subjects: 0
Study: 32584051

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration (ivASA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low impulsivity or aggression
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: First- or second-wave disinhibited traits
Number of subjects: 85
Study: 32584260

Group type: EXPERIMENTAL
Intervention: LIVA 2.0 eHealth lifestyle coaching program in addition to the conventional preventive program.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conventional preventive program of the municipality.
Number of subjects: 340
Study: 32584598

Group type: EXPERIMENTAL
Intervention: TIMP-2 and IGFBP7 biomarkers
Number of subjects: 0
Study: 32585739

Group type: EXPERIMENTAL
Intervention: MPO in the 4th quartile (Q4) on day 1
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Resistin in the 3rd quartile (Q3) and 4th quartile (Q4) on day 2
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: MPO in the 4th quartile (Q4) on day 2
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Resistin in the 4th quartile (Q4) on day 7
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: All quartiles of MPO on day 7
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: High levels of MPO on day 1
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: High levels of resistin on day 1
Number of subjects: 957
Study: 32586337

Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 1
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 2
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Predict Sepsis screening tool 3
Number of subjects: 551
Study: 32586346

Group type: COMPARATOR
Intervention: Active treatment (Pravastatin or Atorvastatin) in PROVE-IT trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active treatment (Losartan) in LIFE trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active treatment in HOPE trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in PROVE-IT trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in LIFE trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in HOPE trial
Number of subjects: 0
Study: 32586767

Group type: EXPERIMENTAL
Intervention: Atezolizumab 15 mg/kg or 1200 mg intravenously every 3 weeks for 16 cycles or until loss of clinical benefit
Number of subjects: 17
Study: 32586892

Group type: EXPERIMENTAL
Intervention: Proactive use of patient-reported outcome measures during follow-up care
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard care (no proactive use of patient-reported outcome measures)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 223
Study: 32586908

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide and dexamethasone
Number of subjects: 0
Study: 32586928

Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP) test
Number of subjects: 260

Group type: COMPARATOR
Intervention: Negative LAMP test
Number of subjects: 260
Study: 32586937

Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Durvalumab 10 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mogamulizumab 1 mg/kg plus Tremelimumab 10 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Mogamulizumab in combination with Durvalumab or Tremelimumab
Number of subjects: 64
Study: 32587571

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 32587748

Group type: EXPERIMENTAL
Intervention: Telehealth-based train-the-trainer mealtime intervention delivered by respite care center volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 32588127

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5625

Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 5625
Study: 32588218

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (high intake of parenteral fluids)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Parenteral nutrition (low intake of parenteral fluids)
Number of subjects: 87
Study: 32588430

Group type: EXPERIMENTAL
Intervention: Patiromer or sodium zirconium cyclosilicate
Number of subjects: 1849

Group type: COMPARATOR
Intervention: Potassium binders (calcium polystyrene sulfonate, sodium polystyrene sulfonate)
Number of subjects: 1849
Study: 32588435

Group type: COMPARATOR
Intervention: Ketogenic diets (KDs)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Ketogenic diets (MAD only)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Classical 4:1 KD
Number of subjects: 932

Group type: COMPARATOR
Intervention: MAD
Number of subjects: 932

Group type: COMPARATOR
Intervention: simplified MAD (sMAD)
Number of subjects: 932

Group type: COMPARATOR
Intervention: MAD plus KetoCal
Number of subjects: 932

Group type: COMPARATOR
Intervention: MAD alone
Number of subjects: 932
Study: 32589156

Group type: EXPERIMENTAL
Intervention: Interactive guidance intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine pediatric care
Number of subjects: 110
Study: 32589310

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 30 mg/day for 3 weeks, tapered off over 12 weeks
Number of subjects: 29
Study: 32589496

Group type: EXPERIMENTAL
Intervention: Attendance of patients with surgical complaints during the COVID-19 outbreak
Number of subjects: 0
Study: 32589738

Group type: EXPERIMENTAL
Intervention: Nevanimibe (ATR-101) at doses of 125, 250, 500, 750, 1000 mg twice daily for 2 weeks followed by a 2-week placebo washout.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo during the 2-week washout period.
Number of subjects: 10
Study: 32589866

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 29
Study: 32589970

Group type: EXPERIMENTAL
Intervention: Hyper-CVAD regimen
Number of subjects: 0
Study: 32590049

Group type: EXPERIMENTAL
Intervention: Romosozumab (EVENITY™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sclerostin antibody
Number of subjects: 0
Study: 32590747

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily on days 1 to 21 of a 28-day cycle
Number of subjects: 21
Study: 32591313

Group type: EXPERIMENTAL
Intervention: Platelet function analyzer 200 during extracorporeal membrane oxygenation
Number of subjects: 0
Study: 32591373

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 8596

Group type: COMPARATOR
Intervention: GLP-1 receptor agonists
Number of subjects: 8596
Study: 32591894

Group type: EXPERIMENTAL
Intervention: TAVI with Edwards SAPIEN 3 prosthesis
Number of subjects: 1745
Study: 32591978

Group type: EXPERIMENTAL
Intervention: Peficitinib (100 mg) administered twice daily from Day 3 to Day 9, coadministered with methotrexate on Day 8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (15-25 mg)
Number of subjects: 0
Study: 32592467

Group type: EXPERIMENTAL
Intervention: Vamorolone
Number of subjects: 39
Study: 32592618

Group type: EXPERIMENTAL
Intervention: DeRidder Burst spinal cord stimulation (B-SCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRS, PCS, EQ-5D, and eight-item Patient-Reported Outcomes Measurement Information System Physical Function
Number of subjects: 0
Study: 32593288

Group type: EXPERIMENTAL
Intervention: Septic group (S group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 71
Study: 32593297

Group type: EXPERIMENTAL
Intervention: ccNexFin monitor
Number of subjects: 23
Study: 32593522

Group type: EXPERIMENTAL
Intervention: Highest quartile of total polyphenols intake (319.9 mg/d)
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Highest quartile of flavonoids intake
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Lowest quartile of total polyphenols intake
Number of subjects: 2231
Study: 32593547

Group type: EXPERIMENTAL
Intervention: Pegvaliase 0.001 to 0.1 mg/kg weekly for 8 weeks, then adjusted to achieve blood Phe concentrations of 60 to 600 μmol/L in PAL-002.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pegvaliase 0.001 to 0.4 mg/kg 5 days/week for 13 weeks in PAL-004.
Number of subjects: 40
Study: 32593675

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with metabolic syndrome (MS)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with high blood pressure
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Postmenopausal women with increased triglycerides
Number of subjects: 291
Study: 32593698

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 434

Group type: COMPARATOR
Intervention: Men
Number of subjects: 434

Group type: COMPARATOR
Intervention: Low CFR in men
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 434
Study: 32594200

Group type: EXPERIMENTAL
Intervention: Postprocedural flushing with crystalloids after oxaliplatin-based HIPEC
Number of subjects: 10

Group type: COMPARATOR
Intervention: No flushing after oxaliplatin-based HIPEC (Control)
Number of subjects: 10
Study: 32594297

Group type: EXPERIMENTAL
Intervention: Celiac patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 45
Study: 32594377

Group type: EXPERIMENTAL
Intervention: Candida antigen immunotherapy
Number of subjects: 44
Study: 32595176

Group type: EXPERIMENTAL
Intervention: WATCHMAN left atrial appendage closure (LAAC) device
Number of subjects: 54
Study: 32595210

Group type: EXPERIMENTAL
Intervention: H. pylori seropositivity
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 74
Study: 32595586

Group type: EXPERIMENTAL
Intervention: Epigenetic intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32595593

Group type: EXPERIMENTAL
Intervention: Modified Timed Up and Go Test
Number of subjects: 0
Study: 32595770

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) at a dosage of 0.469 mg/kg/week for 12 months (group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Growth hormone (GH) therapy (Norditropin®; Novo Nordisk) for 6 months after 6 months untreated (group B)
Number of subjects: 54
Study: 32595879

Group type: EXPERIMENTAL
Intervention: 10-week cognitive stimulation program
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study: 32595918

Group type: EXPERIMENTAL
Intervention: 40 g soy flour (whole soy group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 40 g low-fat milk powder (placebo group)
Number of subjects: 270
Study: 32595978

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 12
Study: 32596803

Group type: EXPERIMENTAL
Intervention: Dynamic transperineal ultrasound (DTU)
Number of subjects: 34
Study: 32596842

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg every 3 weeks)
Number of subjects: 84
Study: 32597029

Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly or less frequent)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (fixed dose, twice-weekly)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Prophylactic rurioctocog alfa pegol (PK-tailored dose regimen)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall haemostatic efficacy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measures
Number of subjects: 216
Study: 32597419

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care radiotherapy ± chemotherapy
Number of subjects: 30
Study: 32597739

Group type: EXPERIMENTAL
Intervention: Food insecure participants with overweight/obesity
Number of subjects: 56

Group type: COMPARATOR
Intervention: Food secure participants with normal weight
Number of subjects: 56
Study: 32598033

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Statin medication
Number of subjects: 8
Study: 32598257

Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg plus mFOLFOX6
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Selinexor 20 mg plus mFOLFOX6
Number of subjects: 10

Group type: COMPARATOR
Intervention: mFOLFOX6
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Selinexor plus mFOLFOX6
Number of subjects: 10
Study: 32599306

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate embolization
Number of subjects: 70
Study: 32600160

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease group
Number of subjects: 131

Group type: COMPARATOR
Intervention: Abdominal aortic aneurysm group
Number of subjects: 131